7.62

1.06% 0.08

After Hours: 7.69 0.07 +0.92%

Cervomed Inc (CRVO)

Overview News Price History Discussions Forecast Stock Split

Cervomed Inc stock is traded at $7.62, with a volume of 92,956. It is up +1.06% in the last 24 hours and down -18.76% over the past month. CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Previous Close:

$7.54

Open:

$7.63

24h Volume:

92,956

Relative Volume:

0.02

Market Cap:

$62.83M

Revenue:

Net Income/Loss:

$-6.42M

P/E Ratio:

-1.3604

EPS:

-5.6013

Net Cash Flow:

$-7.45M

1W Performance:

+5.54%

1M Performance:

-18.76%

6M Performance:

-36.02%

1Y Performance:

-60.44%

1-Day Range:

$7.31

$7.68

1-Week Range:

$7.18

$8.60

52-Week Range:

$1.80

$22.57

Cervomed Inc Stock (CRVO) Company Profile

Name

Cervomed Inc

Sector

Healthcare (1170)

Industry

Biotechnology (667)

Phone

(617) 744-4400

Address

20 PARK PLAZA, BOSTON

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

CRVO's Discussions on Twitter

Compare CRVO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRVO Cervomed Inc	7.62	62.83M	0	-6.42M	-7.45M	-5.6013
VRTX Vertex Pharmaceuticals Inc	450.50	113.52B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	493.22	52.93B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	300.83	39.71B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	585.93	35.00B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	255.86	26.57B	3.81B	-644.79M	-669.77M	-6.24

Cervomed Inc Stock (CRVO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-13-25	Upgrade	Chardan Capital Markets	Neutral → Buy
Dec-17-24	Downgrade	H.C. Wainwright	Buy → Neutral
Dec-11-24	Downgrade	Chardan Capital Markets	Buy → Neutral
Dec-11-24	Downgrade	Morgan Stanley	Overweight → Underweight
Dec-10-24	Downgrade	D. Boral Capital	Buy → Hold
Dec-06-24	Initiated	ROTH MKM	Buy
Dec-05-24	Initiated	H.C. Wainwright	Buy
Sep-18-24	Initiated	Chardan Capital Markets	Buy
Jul-26-24	Initiated	Morgan Stanley	Overweight
Feb-15-24	Initiated	Canaccord Genuity	Buy
Nov-17-20	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-21-18	Initiated	H.C. Wainwright	Buy

View All

Cervomed Inc Stock (CRVO) Latest News

Jun 05, 2025

BNP Paribas Financial Markets Purchases New Position in CervoMed Inc. (NASDAQ:CRVO) - Defense World

Jun 05, 2025

Jun 01, 2025

Reviewing CervoMed (CRVO) and Its Peers - Defense World

Jun 01, 2025

May 21, 2025

CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Analysts - Defense World

May 21, 2025

May 19, 2025

Chardan keeps CervoMed stock Buy rating, $15 target post-results - Investing.com Australia

May 14, 2025

CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | - GuruFocus

May 14, 2025

May 13, 2025

Chardan Adjusts Price Target on CervoMed to $15 From $14, Maintains Buy Rating - marketscreener.com

May 13, 2025

CervoMed (CRVO) Maintains Buy Rating with Stable Price Target | CRVO Stock News - GuruFocus

May 13, 2025

CervoMed Announces $50M Sales Agreement with Leerink - TipRanks

May 13, 2025

Chardan Capital Issues Positive Forecast for CervoMed (NASDAQ:CRVO) Stock Price - Defense World

May 13, 2025

CervoMed Inc. Reports Q1 2025 Financial Results - TipRanks

May 13, 2025

May 12, 2025

Chardan keeps CervoMed stock Buy rating, $15 target post-results By Investing.com - Investing.com South Africa

May 12, 2025